SGLT2 inhibitors and urinary tract infections: resolving the dilemma through aetiological classification

European Heart Journal

17 April 2026

Organised by:

Read full article

Contributors

Yohei Doi

Yohei Doi

Author

Takayuki Hamano

Takayuki Hamano

Author

Yoshitaka Isaka

Yoshitaka Isaka

Author

You may be interested in

Congress Presentation

Use of SGLT2 inhibitors and the incidence of urinary tract infections in patients with heart failure: a pooled analysis of four trials including 26,838 patients

29 June 2021

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

27 August 2023

Congress Presentation

Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk

31 August 2025

Congress Presentation

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study

27 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources